What one share of Bioage Labs holds
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
Bioage Labs’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.26 |
|---|---|
| Profit | −$2.37 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.21 |
| Cash and investments | $8.33 |
| Debt | $0.01 |
| Book value | $8.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$38.17 | $0.10 | −$22.43 | — | −$103.62 |
| 2024 | $0.00 | −$6.63 | $0.03 | −$4.84 | — | — |
| 2025 | $0.25 | −$2.24 | $0.02 | −$2.29 | — | $7.28 |
Common questions about Bioage Labs
How much does one share of Bioage Labs earn?
Over the last 12 months, Bioage Labs lost $2.37 for each share on $0.26 of sales.
Does Bioage Labs pay a dividend?
Bioage Labs didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Bioage Labs’s book value per share?
Bioage Labs’s book value is $8.19 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Bioage Labs have?
Each share of Bioage Labs has $8.33 of cash and investments and $0.01 of debt, as of June 30, 2026.
What is Bioage Labs’s free cash flow per share?
−$2.21 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.